Things To Know About 3 Halal Biotech Stocks

Things To Know About 3 Halal Biotech Stocks

Disclaimer: Please be advised that the information provided in this article is relevant as of the time of its composition. However, it is important to recognize that due to the periodic release of new financial reports on a quarterly basis, the status of the mentioned stocks may undergo changes. Therefore, readers are encouraged to exercise diligence and consult updated financial information before making any investment decisions.

Nowadays, one of the most exciting opportunities offering sectors is the biotech sector. Almost all biotech companies are investigating to develop world-changing drugs, and some of them already have strong drug candidate pipelines. However, small or mid-cap biotech stocks are among the most high-risk stocks in the market. On the other hand, they are the most high-reward stocks as well. If you consider investing in biotech stocks, find halal biotech stocks by reading today’s article. 

Here are three halal biotech stocks for your reference. 

BioMarin Pharmaceutical Inc. (ticker: BMRN)

BioMarin Pharmaceutical, Inc. develops and sells pharmaceuticals for severe diseases and rare medical conditions. The Company’s portfolio consists of commercial products like Aldurazyme, Vimizim, Kuvan, Palynziq, and Voxzogo. Moreover, gene therapy Roctavian, Vosoritide for Achondroplasia, and several new products are in the firm’s pipeline for 2022. The company currently employs 3,045 full-time employees, and it is headquartered in Novato, California.

Seagen Inc. (SGEN)

Seagen Inc. is a biotechnology company that develops therapies to treat cancer. The Company is one of the best-diversified oncology growth stocks in the biotech industry. The firm has launched several commercial products: ADCETRIS, PADCEV, and TUKYSA. Seagen is commercializing ADCETRIS, or brentuximab vedotin, to treat certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Moreover, the firm is also working on developing new therapies for solid tumors and blood-related cancers. The Company currently employs 2,675 full-time employees, and it is headquartered in Bothell, Washington.

Kiniksa Pharmaceuticals Ltd. (KNSA)

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company that engages in developing and selling therapeutic medicines for patients suffering from autoinflammatory and autoimmune diseases. Kiniksa is one of the top biotech value stocks. The company currently employs 215 employees, and its headquarters is in Hamilton, Bermuda.

To read more about Islamic Finance related topics, please click here and visit our academy.

Besides, feel free to sign up for our free stock screening services at